{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:02:33Z","timestamp":1785416553188,"version":"3.56.0"},"reference-count":125,"publisher":"IMR Press","issue":"7","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Biosci. (Landmark Ed)"],"abstract":"<jats:p>Integrins are transmembrane receptors that mediate interactions between the extracellular matrix (ECM) and cells. Integrins are expressed as heterodimers composed of an \u03b1-subunit and a \u03b2-subunit. Based on several \u03b1-subunits and \u03b2-subunits present in mammals, each integrin receptor is functionally distinct with specific ligand-binding and signalling features. Upon activation, integrins regulate diverse cellular functions via the formation of multi-protein assemblies with intracellular signalling proteins at the cell surface. However, integrin dysfunction or aberrant activation is also associated with various pathophysiological consequences. Driven by extensive pre-clinical studies demonstrating integrins as potential therapeutic targets, many drug discovery strategies have already been attempted over the decades with limited success. Molecular complexity and functional redundancy of integrin subunits, along with the toxicity associated with global targeting, remain major hurdles for therapeutic applications, emphasising the need for further understanding of integrin biology. Emerging evidence supports an integrated role of integrins in both innate and adaptive immune systems. Integrins are involved in a diverse array of immunological functions, including leukocyte recruitment, pro-inflammatory signalling, macrophage polarisation, hematopoietic stem cell (HSC) homing, immune homeostasis, Toll-like receptor (TLR) signalling, beta-cell development and function, and immune checkpoint regulation. It has therefore become more apparent why dysregulation of these integrin-mediated functions is often linked to various diseases. Integrin signalling is driven by several crucial downstream kinases, including focal adhesion kinase (FAK), phosphoinositide 3-kinase (PI3K), proto-oncogene tyrosine-protein kinase Src (SRC), and integrin-linked kinase (ILK). Encouraging pre-clinical and clinical studies have demonstrated the translational prospects of targeting integrins indirectly via these downstream molecules. Considering the adverse side effects often resulting from the global targeting of integrins, precise targeting of integrin functions via an indirect or cell-type-specific approach may represent a promising direction for future therapeutic development.<\/jats:p>","DOI":"10.31083\/fbl47669","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:17:49Z","timestamp":1785413869000},"source":"Crossref","is-referenced-by-count":0,"title":["Targeting Integrins in Immunity: Precision Matters for Therapeutic Interventions"],"prefix":"10.31083","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9209-7089","authenticated-orcid":true,"given":"Afsar U.","family":"Ahmed","sequence":"first","affiliation":[{"name":"Department of Microbiology, Anatomy, Physiology and Pharmacology (MAPP), School of Agriculture, Biomedicine and Environment (SABE), La Trobe University, Bundoora, VIC 3086, Australia"},{"name":"Aeterna Health Services Pty Ltd., Bio Innovation Hub, La Trobe University, Bundoora, VIC 3086, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Chastney MR, Kaivola J, Lepp\u00e4nen VM, Ivaska J. The role and regulation of integrins in cell migration and invasion. Nature Reviews. Molecular Cell Biology. 2025; 26: 147\u2013167.","DOI":"10.1038\/s41580-024-00777-1"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Campbell ID, Humphries MJ. Integrin structure, activation, and interactions. Cold Spring Harbor Perspectives in Biology. 2011; 3: a004994.","DOI":"10.1101\/cshperspect.a004994"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Pang X, He X, Qiu Z, Zhang H, Xie R, Liu Z, et al. Targeting integrin pathways: mechanisms and advances in therapy. Signal Transduction and Targeted Therapy. 2023; 8: 1.","DOI":"10.1038\/s41392-022-01259-6"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Bachmann M, Kukkurainen S, Hyt\u00f6nen VP, Wehrle-Haller B. Cell Adhesion by Integrins. Physiological Reviews. 2019; 99: 1655\u20131699.","DOI":"10.1152\/physrev.00036.2018"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Takada Y, Ye X, Simon S. The integrins. Genome Biology. 2007; 8: 215.","DOI":"10.1186\/gb-2007-8-5-215"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Ivaska J, Heino J. Cooperation between integrins and growth factor receptors in signaling and endocytosis. Annual Review of Cell and Developmental Biology. 2011; 27: 291\u2013320.","DOI":"10.1146\/annurev-cellbio-092910-154017"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Kanchanawong P, Calderwood DA. Organization, dynamics and mechanoregulation of integrin-mediated cell-ECM adhesions. Nature Reviews. Molecular Cell Biology. 2023; 24: 142\u2013161.","DOI":"10.1038\/s41580-022-00531-5"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Koch S, Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harbor Perspectives in Medicine. 2012; 2: a006502.","DOI":"10.1101\/cshperspect.a006502"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"B\u00f6kel C, Brown NH. Integrins in development: moving on, responding to, and sticking to the extracellular matrix. Developmental Cell. 2002; 3: 311\u2013321.","DOI":"10.1016\/s1534-5807(02)00265-4"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nature Reviews. Cancer. 2010; 10: 9\u201322.","DOI":"10.1038\/nrc2748"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Hamidi H, Ivaska J. Every step of the way: integrins in cancer progression and metastasis. Nature Reviews. Cancer. 2018; 18: 533\u2013548.","DOI":"10.1038\/s41568-018-0038-z"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Chen JR, Zhao JT, Xie ZZ. Integrin-mediated cancer progression as a specific target in clinical therapy. Biomedicine & Pharmacotherapy. 2022; 155: 113745.","DOI":"10.1016\/j.biopha.2022.113745"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Liu F, Wu Q, Dong Z, Liu K. Integrins in cancer: Emerging mechanisms and therapeutic opportunities. Pharmacology & Therapeutics. 2023; 247: 108458.","DOI":"10.1016\/j.pharmthera.2023.108458"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Chen J, Green J, Yurdagul A Jr, Albert P, McInnis MC, Orr AW. \u03b1v\u03b23 Integrins Mediate Flow-Induced NF-\u03baB Activation, Proinflammatory Gene Expression, and Early Atherogenic Inflammation. The American Journal of Pathology. 2015; 185: 2575\u20132589.","DOI":"10.1016\/j.ajpath.2015.05.013"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Bhullar IS, Li YS, Miao H, Zandi E, Kim M, Shyy JY, et al. Fluid shear stress activation of IkappaB kinase is integrin-dependent. The Journal of Biological Chemistry. 1998; 273: 30544\u201330549.","DOI":"10.1074\/jbc.273.46.30544"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Jamasbi J, Ayabe K, Goto S, Nieswandt B, Peter K, Siess W. Platelet receptors as therapeutic targets: Past, present and future. Thrombosis and Haemostasis. 2017; 117: 1249\u20131257.","DOI":"10.1160\/TH16-12-0911"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Henderson NC, Sheppard D. Integrin-mediated regulation of TGF\u03b2 in fibrosis. Biochimica et Biophysica Acta. 2013; 1832: 891\u2013896.","DOI":"10.1016\/j.bbadis.2012.10.005"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Madala SK, Korfhagen TR, Schmidt S, Davidson C, Edukulla R, Ikegami M, et al. Inhibition of the \u03b1v\u03b26 integrin leads to limited alteration of TGF-\u03b1-induced pulmonary fibrosis. American Journal of Physiology. Lung Cellular and Molecular Physiology. 2014; 306: L726\u2013L735.","DOI":"10.1152\/ajplung.00357.2013"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Bansal R, Nakagawa S, Yazdani S, van Baarlen J, Venkatesh A, Koh AP, et al. Integrin alpha 11 in the regulation of the myofibroblast phenotype: implications for fibrotic diseases. Experimental & Molecular Medicine. 2017; 49: e396.","DOI":"10.1038\/emm.2017.213"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Zheng G, Zhang J, Zhao H, Wang H, Pang M, Qiao X, et al. \u03b13 Integrin of Cell-Cell Contact Mediates Kidney Fibrosis by Integrin-Linked Kinase in Proximal Tubular E-Cadherin Deficient Mice. The American Journal of Pathology. 2016; 186: 1847\u20131860.","DOI":"10.1016\/j.ajpath.2016.03.015"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Slack RJ, Macdonald SJF, Roper JA, Jenkins RG, Hatley RJD. Emerging therapeutic opportunities for integrin inhibitors. Nature Reviews. Drug Discovery. 2022; 21: 60\u201378.","DOI":"10.1038\/s41573-021-00284-4"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Kereiakes DJ, Henry TD, DeMaria AN, Bentur O, Carlson M, Seng Yue C, et al. First Human Use of RUC-4: A Nonactivating Second-Generation Small-Molecule Platelet Glycoprotein IIb\/IIIa (Integrin \u03b1IIb\u03b23) Inhibitor Designed for Subcutaneous Point-of-Care Treatment of ST-Segment-Elevation Myocardial Infarction. Journal of the American Heart Association. 2020; 9: e016552.","DOI":"10.1161\/JAHA.120.016552"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Zhu J, Choi WS, McCoy JG, Negri A, Zhu J, Naini S, et al. Structure-guided design of a high-affinity platelet integrin \u03b1IIb\u03b23 receptor antagonist that disrupts Mg2\u207a binding to the MIDAS. Science Translational Medicine. 2012; 4: 125ra32.","DOI":"10.1126\/scitranslmed.3003576"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Matsuoka K, Watanabe M, Ohmori T, Nakajima K, Ishida T, Ishiguro Y, et al. AJM300 (carotegrast methyl), an oral antagonist of \u03b14-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. The Lancet. Gastroenterology & Hepatology. 2022; 7: 648\u2013657.","DOI":"10.1016\/S2468-1253(22)00022-X"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Goodman SL, Picard M. Integrins as therapeutic targets. Trends in Pharmacological Sciences. 2012; 33: 405\u2013412.","DOI":"10.1016\/j.tips.2012.04.002"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Shattil SJ, Kim C, Ginsberg MH. The final steps of integrin activation: the end game. Nature Reviews. Molecular Cell Biology. 2010; 11: 288\u2013300.","DOI":"10.1038\/nrm2871"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Moreno-Layseca P, Icha J, Hamidi H, Ivaska J. Integrin trafficking in cells and tissues. Nature Cell Biology. 2019; 21: 122\u2013132.","DOI":"10.1038\/s41556-018-0223-z"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Lin FY, Li J, Xie Y, Zhu J, Huong Nguyen TT, Zhang Y, et al. A general chemical principle for creating closure-stabilizing integrin inhibitors. Cell. 2022; 185: 3533\u20133550.e27.","DOI":"10.1016\/j.cell.2022.08.008"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Danen EHJ. Integrins: regulators of tissue function and cancer progression. Current Pharmaceutical Design. 2005; 11: 881\u2013891.","DOI":"10.2174\/1381612053381756"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Li ZH, Zhou Y, Ding YX, Guo QL, Zhao L. Roles of integrin in tumor development and the target inhibitors. Chinese Journal of Natural Medicines. 2019; 17: 241\u2013251.","DOI":"10.1016\/S1875-5364(19)30028-7"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Ellert-Miklaszewska A, Poleszak K, Pasierbinska M, Kaminska B. Integrin Signaling in Glioma Pathogenesis: From Biology to Therapy. International Journal of Molecular Sciences. 2020; 21: 888.","DOI":"10.3390\/ijms21030888"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Truong HH, Xiong J, Ghotra VPS, Nirmala E, Haazen L, Le D\u00e9v\u00e9dec SE, et al. \u03b21 integrin inhibition elicits a prometastatic switch through the TGF\u03b2-miR-200-ZEB network in E-cadherin-positive triple-negative breast cancer. Science Signaling. 2014; 7: ra15.","DOI":"10.1126\/scisignal.2004751"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Mitroulis I, Alexaki VI, Kourtzelis I, Ziogas A, Hajishengallis G, Chavakis T. Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease. Pharmacology & Therapeutics. 2015; 147: 123\u2013135.","DOI":"10.1016\/j.pharmthera.2014.11.008"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Fagerholm SC, Guenther C, Llort Asens M, Savinko T, Uotila LM. Beta2-Integrins and Interacting Proteins in Leukocyte Trafficking, Immune Suppression, and Immunodeficiency Disease. Frontiers in Immunology. 2019; 10: 254.","DOI":"10.3389\/fimmu.2019.00254"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Sun H, Zhi K, Hu L, Fan Z. The Activation and Regulation of \u03b22 Integrins in Phagocytes and Phagocytosis. Frontiers in Immunology. 2021; 12: 633639.","DOI":"10.3389\/fimmu.2021.633639"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Sun Q, Lu Z, Ma L, Xue D, Liu C, Ye C, et al. Integrin \u03b26 deficiency protects mice from experimental colitis and colitis-associated carcinoma by altering macrophage polarization. Frontiers in Oncology. 2023; 13: 1190229.","DOI":"10.3389\/fonc.2023.1190229"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Bednarczyk M, Bolduan V, Haist M, Stege H, Hieber C, Johann L, et al. \u03b22 Integrins on Dendritic Cells Modulate Cytokine Signaling and Inflammation-Associated Gene Expression, and Are Required for Induction of Autoimmune Encephalomyelitis. Cells. 2022; 11: 2188.","DOI":"10.3390\/cells11142188"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Schmidt S, Moser M, Sperandio M. The molecular basis of leukocyte recruitment and its deficiencies. Molecular Immunology. 2013; 55: 49\u201358.","DOI":"10.1016\/j.molimm.2012.11.006"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Fekadu J, Modlich U, Bader P, Bakhtiar S. Understanding the Role of LFA-1 in Leukocyte Adhesion Deficiency Type I (LAD I): Moving towards Inflammation? International Journal of Molecular Sciences. 2022; 23: 3578.","DOI":"10.3390\/ijms23073578"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Kuijpers TW, van Bruggen R, Kamerbeek N, Tool ATJ, Hicsonmez G, Gurgey A, et al. Natural history and early diagnosis of LAD-1\/variant syndrome. Blood. 2007; 109: 3529\u20133537.","DOI":"10.1182\/blood-2006-05-021402"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Kuijpers TW, Van Lier RA, Hamann D, de Boer M, Thung LY, Weening RS, et al. Leukocyte adhesion deficiency type 1 (LAD-1)\/variant. A novel immunodeficiency syndrome characterized by dysfunctional beta2 integrins. The Journal of Clinical Investigation. 1997; 100: 1725\u20131733.","DOI":"10.1172\/JCI119697"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Hanna S, Etzioni A. Leukocyte adhesion deficiencies. Annals of the New York Academy of Sciences. 2012; 1250: 50\u201355.","DOI":"10.1111\/j.1749-6632.2011.06389.x"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Diaferia GR, Jimenez-Caliani AJ, Ranjitkar P, Yang W, Hardiman G, Rhodes CJ, et al. \u03b21 integrin is a crucial regulator of pancreatic \u03b2-cell expansion. Development (Cambridge, England). 2013; 140: 3360\u20133372.","DOI":"10.1242\/dev.098533"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Peart J, Li J, Lee H, Riopel M, Feng ZC, Wang R. Critical role of \u03b21 integrin in postnatal beta-cell function and expansion. Oncotarget. 2017; 8: 62939\u201362952.","DOI":"10.18632\/oncotarget.17969"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Rondas D, Tomas A, Halban PA. Focal adhesion remodeling is crucial for glucose-stimulated insulin secretion and involves activation of focal adhesion kinase and paxillin. Diabetes. 2011; 60: 1146\u20131157.","DOI":"10.2337\/db10-0946"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Saleem S, Li J, Yee SP, Fellows GF, Goodyer CG, Wang R. beta1 integrin\/FAK\/ERK signalling pathway is essential for human fetal islet cell differentiation and survival. The Journal of Pathology. 2009; 219: 182\u2013192.","DOI":"10.1002\/path.2577"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Del Carlo M, Schwartz D, Erickson EA, Loeser RF. Endogenous production of reactive oxygen species is required for stimulation of human articular chondrocyte matrix metalloproteinase production by fibronectin fragments. Free Radical Biology & Medicine. 2007; 42: 1350\u20131358.","DOI":"10.1016\/j.freeradbiomed.2007.01.035"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Loeser RF. Integrins and chondrocyte-matrix interactions in articular cartilage. Matrix Biology: Journal of the International Society for Matrix Biology. 2014; 39: 11\u201316.","DOI":"10.1016\/j.matbio.2014.08.007"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Sumsuzzman DM, Khan ZA, Choi J, Hong Y. Assessment of functional roles and therapeutic potential of integrin receptors in osteoarthritis: A systematic review and meta-analysis of preclinical studies. Ageing Research Reviews. 2022; 81: 101729.","DOI":"10.1016\/j.arr.2022.101729"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Chung KJ, Mitroulis I, Wiessner JR, Zheng YY, Siegert G, Sperandio M, et al. A novel pathway of rapid TLR-triggered activation of integrin-dependent leukocyte adhesion that requires Rap1 GTPase. Molecular Biology of the Cell. 2014; 25: 2948\u20132955.","DOI":"10.1091\/mbc.E14-04-0867"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Kanayama M, Morimoto J, Matsui Y, Ikesue M, Danzaki K, Kurotaki D, et al. \u03b19\u03b21 integrin-mediated signaling serves as an intrinsic regulator of pathogenic Th17 cell generation. Journal of Immunology (Baltimore, Md.: 1950). 2011; 187: 5851\u20135864.","DOI":"10.4049\/jimmunol.1101524"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Lerman YV, Lim K, Hyun YM, Falkner KL, Yang H, Pietropaoli AP, et al. Sepsis lethality via exacerbated tissue infiltration and TLR-induced cytokine production by neutrophils is integrin \u03b13\u03b21-dependent. Blood. 2014; 124: 3515\u20133523.","DOI":"10.1182\/blood-2014-01-552943"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Yee NK, Hamerman JA. \u03b2(2) integrins inhibit TLR responses by regulating NF-\u03baB pathway and p38 MAPK activation. European Journal of Immunology. 2013; 43: 779\u2013792.","DOI":"10.1002\/eji.201242550"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Ghobadi A, Rettig MP, Cooper ML, Holt MS, Ritchey JK, Eissenberg L, et al. Bortezomib is a rapid mobilizer of hematopoietic stem cells in mice via modulation of the VCAM-1\/VLA-4 axis. Blood. 2014; 124: 2752\u20132754.","DOI":"10.1182\/blood-2014-08-595967"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"LaFoya B, Munroe JA, Miyamoto A, Detweiler MA, Crow JJ, Gazdik T, et al. Beyond the Matrix: The Many Non-ECM Ligands for Integrins. International Journal of Molecular Sciences. 2018; 19: 449.","DOI":"10.3390\/ijms19020449"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Rettig MP, Ansstas G, DiPersio JF. Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4. Leukemia. 2012; 26: 34\u201353.","DOI":"10.1038\/leu.2011.197"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Sheremata WA, Minagar A, Alexander JS, Vollmer T. The role of alpha-4 integrin in the aetiology of multiple sclerosis: current knowledge and therapeutic implications. CNS Drugs. 2005; 19: 909\u2013922.","DOI":"10.2165\/00023210-200519110-00002"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Ruan S, Lin M, Zhu Y, Lum L, Thakur A, Jin R, et al. Integrin \u03b24-Targeted Cancer Immunotherapies Inhibit Tumor Growth and Decrease Metastasis. Cancer Research. 2020; 80: 771\u2013783.","DOI":"10.1158\/0008-5472.CAN-19-1145"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Scribano ML. Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence. World Journal of Gastroenterology. 2018; 24: 2457\u20132467.","DOI":"10.3748\/wjg.v24.i23.2457"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Vermeire S, O'Byrne S, Keir M, Williams M, Lu TT, Mansfield JC, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet (London, England). 2014; 384: 309\u2013318.","DOI":"10.1016\/S0140-6736(14)60661-9"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Braun A, Dewert N, Brunnert F, Schnabel V, Hardenberg JH, Richter B, et al. Integrin \u03b1E(CD103) Is Involved in Regulatory T-Cell Function in Allergic Contact Hypersensitivity. The Journal of Investigative Dermatology. 2015; 135: 2982\u20132991.","DOI":"10.1038\/jid.2015.287"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Huehn J, Siegmund K, Lehmann JCU, Siewert C, Haubold U, Feuerer M, et al. Developmental stage, phenotype, and migration distinguish naive- and effector\/memory-like CD4+ regulatory T cells. The Journal of Experimental Medicine. 2004; 199: 303\u2013313.","DOI":"10.1084\/jem.20031562"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Kim Y, Shin Y, Kang GH. Prognostic significance of CD103+ immune cells in solid tumor: a systemic review and meta-analysis. Scientific Reports. 2019; 9: 3808.","DOI":"10.1038\/s41598-019-40527-4"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Lehmann J, Huehn J, de la Rosa M, Maszyna F, Kretschmer U, Krenn V, et al. Expression of the integrin alpha Ebeta 7 identifies unique subsets of CD25+ as well as CD25- regulatory T cells. Proceedings of the National Academy of Sciences of the United States of America. 2002; 99: 13031\u201313036.","DOI":"10.1073\/pnas.192162899"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Bednarczyk M, Stege H, Grabbe S, Bros M. \u03b22 Integrins-Multi-Functional Leukocyte Receptors in Health and Disease. International Journal of Molecular Sciences. 2020; 21: 1402.","DOI":"10.3390\/ijms21041402"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Fraemohs L, Koenen RR, Ostermann G, Heinemann B, Weber C. The functional interaction of the beta 2 integrin lymphocyte function-associated antigen-1 with junctional adhesion molecule-A is mediated by the I domain. Journal of Immunology (Baltimore, Md.: 1950). 2004; 173: 6259\u20136264.","DOI":"10.4049\/jimmunol.173.10.6259"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Kummer D, Ebnet K. Junctional Adhesion Molecules (JAMs): The JAM-Integrin Connection. Cells. 2018; 7: 25.","DOI":"10.3390\/cells7040025"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Altieri DC, Agbanyo FR, Plescia J, Ginsberg MH, Edgington TS, Plow EF. A unique recognition site mediates the interaction of fibrinogen with the leukocyte integrin Mac-1 (CD11b\/CD18). The Journal of Biological Chemistry. 1990; 265: 12119\u201312122.","DOI":"10.1016\/S0021-9258(19)38316-4"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Chavakis T, Bierhaus A, Al-Fakhri N, Schneider D, Witte S, Linn T, et al. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. The Journal of Experimental Medicine. 2003; 198: 1507\u20131515.","DOI":"10.1084\/jem.20030800"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Kanse SM, Matz RL, Preissner KT, Peter K. Promotion of leukocyte adhesion by a novel interaction between vitronectin and the beta2 integrin Mac-1 (alphaMbeta2, CD11b\/CD18). Arteriosclerosis, Thrombosis, and Vascular Biology. 2004; 24: 2251\u20132256.","DOI":"10.1161\/01.ATV.0000146529.68729.8b"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"Peter K, Schwarz M, Conradt C, Nordt T, Moser M, K\u00fcbler W, et al. Heparin inhibits ligand binding to the leukocyte integrin Mac-1 (CD11b\/CD18). Circulation. 1999; 100: 1533\u20131539.","DOI":"10.1161\/01.cir.100.14.1533"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"Wolf D, Anto-Michel N, Blankenbach H, Wiedemann A, Buscher K, Hohmann JD, et al. A ligand-specific blockade of the integrin Mac-1 selectively targets pathologic inflammation while maintaining protective host-defense. Nature Communications. 2018; 9: 525.","DOI":"10.1038\/s41467-018-02896-8"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"Lishko VK, Podolnikova NP, Yakubenko VP, Yakovlev S, Medved L, Yadav SP, et al. Multiple binding sites in fibrinogen for integrin alphaMbeta2 (Mac-1). The Journal of Biological Chemistry. 2004; 279: 44897\u201344906.","DOI":"10.1074\/jbc.M408012200"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"Walzog B, Schuppan D, Heimpel C, Hafezi-Moghadam A, Gaehtgens P, Ley K. The leukocyte integrin Mac-1 (CD11b\/CD18) contributes to binding of human granulocytes to collagen. Experimental Cell Research. 1995; 218: 28\u201338.","DOI":"10.1006\/excr.1995.1127"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"Simon DI. Opening the field of integrin biology to \"biased agonism\". Circulation Research. 2011; 109: 1199\u20131201.","DOI":"10.1161\/CIRCRESAHA.111.257980"},{"key":"ref76","doi-asserted-by":"publisher","unstructured":"Bajic G, Yatime L, Sim RB, Vorup-Jensen T, Andersen GR. Structural insight on the recognition of surface-bound opsonins by the integrin I domain of complement receptor 3. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110: 16426\u201316431.","DOI":"10.1073\/pnas.1311261110"},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"Lamers C, Pl\u00fcss CJ, Ricklin D. The Promiscuous Profile of Complement Receptor 3 in Ligand Binding, Immune Modulation, and Pathophysiology. Frontiers in Immunology. 2021; 12: 662164.","DOI":"10.3389\/fimmu.2021.662164"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"Cui K, Ardell CL, Podolnikova NP, Yakubenko VP. Distinct Migratory Properties of M1, M2, and Resident Macrophages Are Regulated by \u03b1D\u03b22 and \u03b1M\u03b22 Integrin-Mediated Adhesion. Frontiers in Immunology. 2018; 9: 2650.","DOI":"10.3389\/fimmu.2018.02650"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"Szabo PA, Miron M, Farber DL. Location, location, location: Tissue resident memory T cells in mice and humans. Science Immunology. 2019; 4: eaas9673.","DOI":"10.1126\/sciimmunol.aas9673"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"Cepek KL, Shaw SK, Parker CM, Russell GJ, Morrow JS, Rimm DL, et al. Adhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the alpha E beta 7 integrin. Nature. 1994; 372: 190\u2013193.","DOI":"10.1038\/372190a0"},{"key":"ref81","doi-asserted-by":"publisher","unstructured":"El-Asady R, Yuan R, Liu K, Wang D, Gress RE, Lucas PJ, et al. TGF-{beta}-dependent CD103 expression by CD8(+) T cells promotes selective destruction of the host intestinal epithelium during graft-versus-host disease. The Journal of Experimental Medicine. 2005; 201: 1647\u20131657.","DOI":"10.1084\/jem.20041044"},{"key":"ref82","doi-asserted-by":"publisher","unstructured":"Boutet M, Gauthier L, Leclerc M, Gros G, de Montpreville V, Th\u00e9ret N, et al. TGF\u03b2 Signaling Intersects with CD103 Integrin Signaling to Promote T-Lymphocyte Accumulation and Antitumor Activity in the Lung Tumor Microenvironment. Cancer Research. 2016; 76: 1757\u20131769.","DOI":"10.1158\/0008-5472.CAN-15-1545"},{"key":"ref83","doi-asserted-by":"publisher","unstructured":"Le Floc'h A, Jalil A, Franciszkiewicz K, Validire P, Vergnon I, Mami-Chouaib F. Minimal engagement of CD103 on cytotoxic T lymphocytes with an E-cadherin-Fc molecule triggers lytic granule polarization via a phospholipase Cgamma-dependent pathway. Cancer Research. 2011; 71: 328\u2013338.","DOI":"10.1158\/0008-5472.CAN-10-2457"},{"key":"ref84","doi-asserted-by":"publisher","unstructured":"Le Floc'h A, Jalil A, Vergnon I, Le Maux Chansac B, Lazar V, Bismuth G, et al. Alpha E beta 7 integrin interaction with E-cadherin promotes antitumor CTL activity by triggering lytic granule polarization and exocytosis. The Journal of Experimental Medicine. 2007; 204: 559\u2013570.","DOI":"10.1084\/jem.20061524"},{"key":"ref85","doi-asserted-by":"publisher","unstructured":"Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Medicine. 2004; 10: 942\u2013949.","DOI":"10.1038\/nm1093"},{"key":"ref86","doi-asserted-by":"publisher","unstructured":"Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, Arfi V, et al. Regulatory T cells recruited through CCL22\/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Research. 2009; 69: 2000\u20132009.","DOI":"10.1158\/0008-5472.CAN-08-2360"},{"key":"ref87","doi-asserted-by":"publisher","unstructured":"Ho J, Kurtz CC, Naganuma M, Ernst PB, Cominelli F, Rivera-Nieves J. A CD8+\/CD103high T cell subset regulates TNF-mediated chronic murine ileitis. Journal of Immunology (Baltimore, Md.: 1950). 2008; 180: 2573\u20132580.","DOI":"10.4049\/jimmunol.180.4.2573"},{"key":"ref88","doi-asserted-by":"publisher","unstructured":"Liu Y, Lan Q, Lu L, Chen M, Xia Z, Ma J, et al. Phenotypic and functional characteristic of a newly identified CD8+ Foxp3- CD103+ regulatory T cells. Journal of Molecular Cell Biology. 2014; 6: 81\u201392.","DOI":"10.1093\/jmcb\/mjt026"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"Picarella D, Hurlbut P, Rottman J, Shi X, Butcher E, Ringler DJ. Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells. Journal of Immunology (Baltimore, Md.: 1950). 1997; 158: 2099\u20132106.","DOI":"10.4049\/jimmunol.158.5.2099"},{"key":"ref90","doi-asserted-by":"publisher","unstructured":"Sydora BC, Wagner N, Lohler J, Yakoub G, Kronenberg M, Muller W, et al. beta7 Integrin expression is not required for the localization of T cells to the intestine and colitis pathogenesis. Clinical and Experimental Immunology. 2002; 129: 35\u201342.","DOI":"10.1046\/j.1365-2249.2002.01892.x"},{"key":"ref91","doi-asserted-by":"publisher","unstructured":"Park C, Cheung KP, Limon N, Costanzo A, Barba C, Miranda N, et al. Obesity Modulates Intestinal Intraepithelial T Cell Persistence, CD103 and CCR9 Expression, and Outcome in Dextran Sulfate Sodium-Induced Colitis. Journal of Immunology (Baltimore, Md.: 1950). 2019; 203: 3427\u20133435.","DOI":"10.4049\/jimmunol.1900082"},{"key":"ref92","doi-asserted-by":"publisher","unstructured":"Krishnamurthy M, Wang R. Integrins and extracellular matrices in pancreatic tissue engineering. Frontiers in Bioscience (Scholar Edition). 2009; 1: 477\u2013491.","DOI":"10.2741\/s39"},{"key":"ref93","doi-asserted-by":"publisher","unstructured":"Nolte M, Margadant C. Controlling Immunity and Inflammation through Integrin-Dependent Regulation of TGF-\u03b2. Trends in Cell Biology. 2020; 30: 49\u201359.","DOI":"10.1016\/j.tcb.2019.10.002"},{"key":"ref94","unstructured":"Weinstock-Guttman B. An update on new and emerging therapies for relapsing-remitting multiple sclerosis. The American Journal of Managed Care. 2013; 19: s343\u2013s354."},{"key":"ref95","doi-asserted-by":"publisher","unstructured":"Rubin DT, Dotan I, DuVall A, Bouhnik Y, Radford-Smith G, Higgins PDR, et al. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. The Lancet. Gastroenterology & Hepatology. 2022; 7: 17\u201327.","DOI":"10.1016\/S2468-1253(21)00338-1"},{"key":"ref96","doi-asserted-by":"publisher","unstructured":"Sandborn WJ, Cyrille M, Hansen MB, Feagan BG, Loftus EV Jr, Rogler G, et al. Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis. Gastroenterology. 2019; 156: 946\u2013957.e18.","DOI":"10.1053\/j.gastro.2018.11.035"},{"key":"ref97","doi-asserted-by":"publisher","unstructured":"Ley K, Rivera-Nieves J, Sandborn WJ, Shattil S. Integrin-based therapeutics: biological basis, clinical use and new drugs. Nature Reviews. Drug Discovery. 2016; 15: 173\u2013183.","DOI":"10.1038\/nrd.2015.10"},{"key":"ref98","doi-asserted-by":"publisher","unstructured":"Humphries JD, Chastney MR, Askari JA, Humphries MJ. Signal transduction via integrin adhesion complexes. Current Opinion in Cell Biology. 2019; 56: 14\u201321.","DOI":"10.1016\/j.ceb.2018.08.004"},{"key":"ref99","doi-asserted-by":"publisher","unstructured":"Lopez-Mejia IC, Pijuan J, Navaridas R, Santacana M, Gatius S, Velasco A, et al. Oxidative stress-induced FAK activation contributes to uterine serous carcinoma aggressiveness. Molecular Oncology. 2023; 17: 98\u2013118.","DOI":"10.1002\/1878-0261.13346"},{"key":"ref100","doi-asserted-by":"publisher","unstructured":"Canel M, Taggart D, Sims AH, Lonergan DW, Waizenegger IC, Serrels A. T-cell co-stimulation in combination with targeting FAK drives enhanced anti-tumor immunity. elife. 2020; 9: e48092.","DOI":"10.7554\/eLife.48092"},{"key":"ref101","doi-asserted-by":"publisher","unstructured":"Rugo HS, Andr\u00e9 F, Yamashita T, Cerda H, Toledano I, Stemmer SM, et al. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Annals of Oncology: Official Journal of the European Society for Medical Oncology. 2020; 31: 1001\u20131010.","DOI":"10.1016\/j.annonc.2020.05.001"},{"key":"ref102","doi-asserted-by":"publisher","unstructured":"Fornier MN, Morris PG, Abbruzzi A, D'Andrea G, Gilewski T, Bromberg J, et al. A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer. Annals of Oncology: Official Journal of the European Society for Medical Oncology. 2011; 22: 2575\u20132581.","DOI":"10.1093\/annonc\/mdr018"},{"key":"ref103","doi-asserted-by":"publisher","unstructured":"Somlo G, Atzori F, Strauss LC, Geese WJ, Specht JM, Gradishar WJ, et al. Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2013; 19: 1884\u20131893.","DOI":"10.1158\/1078-0432.CCR-12-0652"},{"key":"ref104","doi-asserted-by":"publisher","unstructured":"Alasseiri M, Ahmed AU, Williams BRG. Mechanisms and consequences of constitutive activation of integrin-linked kinase in acute myeloid leukemia. Cytokine & Growth Factor Reviews. 2018; 43: 1\u20137.","DOI":"10.1016\/j.cytogfr.2018.06.001"},{"key":"ref105","doi-asserted-by":"publisher","unstructured":"Almasabi S, Ahmed AU, Boyd R, Williams BRG. A Potential Role for Integrin-Linked Kinase in Colorectal Cancer Growth and Progression via Regulating Senescence and Immunity. Frontiers in Genetics. 2021; 12: 638558.","DOI":"10.3389\/fgene.2021.638558"},{"key":"ref106","doi-asserted-by":"publisher","unstructured":"Kalra J, Warburton C, Fang K, Edwards L, Daynard T, Waterhouse D, et al. QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model. Breast Cancer Research: BCR. 2009; 11: R25.","DOI":"10.1186\/bcr2252"},{"key":"ref107","doi-asserted-by":"publisher","unstructured":"Lee SL, Hsu EC, Chou CC, Chuang HC, Bai LY, Kulp SK, et al. Identification and characterization of a novel integrin-linked kinase inhibitor. Journal of Medicinal Chemistry. 2011; 54: 6364\u20136374.","DOI":"10.1021\/jm2007744"},{"key":"ref108","doi-asserted-by":"crossref","unstructured":"Liu J, Costello PC, Pham NA, Pintillie M, Jabali M, Sanghera J, et al. Integrin-linked kinase inhibitor KP-392 demonstrates clinical benefits in an orthotopic human non-small cell lung cancer model. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer. 2006; 1: 771\u2013779.","DOI":"10.1097\/01243894-200610000-00004"},{"key":"ref109","doi-asserted-by":"publisher","unstructured":"Tan C, Cruet-Hennequart S, Troussard A, Fazli L, Costello P, Sutton K, et al. Regulation of tumor angiogenesis by integrin-linked kinase (ILK). Cancer Cell. 2004; 5: 79\u201390.","DOI":"10.1016\/s1535-6108(03)00281-2"},{"key":"ref110","doi-asserted-by":"publisher","unstructured":"Margraf A, Germena G, Drexler HCA, Rossaint J, Ludwig N, Prystaj B, et al. The integrin-linked kinase is required for chemokine-triggered high-affinity conformation of the neutrophil \u03b22-integrin LFA-1. Blood. 2020; 136: 2200\u20132205.","DOI":"10.1182\/blood.2020004948"},{"key":"ref111","doi-asserted-by":"publisher","unstructured":"Novak A, Hsu SC, Leung-Hagesteijn C, Radeva G, Papkoff J, Montesano R, et al. Cell adhesion and the integrin-linked kinase regulate the LEF-1 and beta-catenin signaling pathways. Proceedings of the National Academy of Sciences of the United States of America. 1998; 95: 4374\u20134379.","DOI":"10.1073\/pnas.95.8.4374"},{"key":"ref112","doi-asserted-by":"publisher","unstructured":"Yu S, Zhou X, Steinke FC, Liu C, Chen SC, Zagorodna O, et al. The TCF-1 and LEF-1 transcription factors have cooperative and opposing roles in T cell development and malignancy. Immunity. 2012; 37: 813\u2013826.","DOI":"10.1016\/j.immuni.2012.08.009"},{"key":"ref113","doi-asserted-by":"publisher","unstructured":"Ahmed AU, Sarvestani ST, Gantier MP, Williams BRG, Hannigan GE. Integrin-linked kinase modulates lipopolysaccharide- and Helicobacter pylori-induced nuclear factor \u03baB-activated tumor necrosis factor-\u03b1 production via regulation of p65 serine 536 phosphorylation. The Journal of Biological Chemistry. 2014; 289: 27776\u201327793.","DOI":"10.1074\/jbc.M114.574541"},{"key":"ref114","doi-asserted-by":"publisher","unstructured":"Ahmed AU, Yim HCH, Alorro M, Ernst M, Williams BRG. Integrin-Linked Kinase Expression in Myeloid Cells Promotes Inflammatory Signaling during Experimental Colitis. Journal of Immunology (Baltimore, Md.: 1950). 2017; 199: 2128\u20132139.","DOI":"10.4049\/jimmunol.1700125"},{"key":"ref115","doi-asserted-by":"publisher","unstructured":"Ahmed AU, Almasabi S, Firestein R, Williams BRG. Integrin-linked kinase expression in myeloid cells promotes colon tumorigenesis. Frontiers in Immunology. 2023; 14: 1270194.","DOI":"10.3389\/fimmu.2023.1270194"},{"key":"ref116","doi-asserted-by":"publisher","unstructured":"Almasabi S, Boyd R, Ahmed AU, Williams BRG. Integrin-Linked Kinase Expression Characterizes the Immunosuppressive Tumor Microenvironment in Colorectal Cancer and Regulates PD-L1 Expression and Immune Cell Cytotoxicity. Frontiers in Oncology. 2022; 12: 836005.","DOI":"10.3389\/fonc.2022.836005"},{"key":"ref117","doi-asserted-by":"publisher","unstructured":"Weis SM, Cheresh DA. \u03b1V integrins in angiogenesis and cancer. Cold Spring Harbor Perspectives in Medicine. 2011; 1: a006478.","DOI":"10.1101\/cshperspect.a006478"},{"key":"ref118","doi-asserted-by":"publisher","unstructured":"Temming K, Schiffelers RM, Molema G, Kok RJ. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 2005; 8: 381\u2013402.","DOI":"10.1016\/j.drup.2005.10.002"},{"key":"ref119","doi-asserted-by":"publisher","unstructured":"Zhang F, Lin YA, Kannan S, Kannan RM. Targeting specific cells in the brain with nanomedicines for CNS therapies. Journal of Controlled Release: Official Journal of the Controlled Release Society. 2016; 240: 212\u2013226.","DOI":"10.1016\/j.jconrel.2015.12.013"},{"key":"ref120","doi-asserted-by":"publisher","unstructured":"Liu Y, Ran R, Chen J, Kuang Q, Tang J, Mei L, et al. Paclitaxel loaded liposomes decorated with a multifunctional tandem peptide for glioma targeting. Biomaterials. 2014; 35: 4835\u20134847.","DOI":"10.1016\/j.biomaterials.2014.02.031"},{"key":"ref121","doi-asserted-by":"publisher","unstructured":"Gao JQ, Lv Q, Li LM, Tang XJ, Li FZ, Hu YL, et al. Glioma targeting and blood-brain barrier penetration by dual-targeting doxorubincin liposomes. Biomaterials. 2013; 34: 5628\u20135639.","DOI":"10.1016\/j.biomaterials.2013.03.097"},{"key":"ref122","doi-asserted-by":"publisher","unstructured":"Boado RJ, Hui EKW, Lu JZ, Sumbria RK, Pardridge WM. Blood-brain barrier molecular trojan horse enables imaging of brain uptake of radioiodinated recombinant protein in the rhesus monkey. Bioconjugate Chemistry. 2013; 24: 1741\u20131749.","DOI":"10.1021\/bc400319d"},{"key":"ref123","doi-asserted-by":"publisher","unstructured":"Drappatz J, Brenner A, Wong ET, Eichler A, Schiff D, Groves MD, et al. Phase I study of GRN1005 in recurrent malignant glioma. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2013; 19: 1567\u20131576.","DOI":"10.1158\/1078-0432.CCR-12-2481"},{"key":"ref124","doi-asserted-by":"publisher","unstructured":"Zong T, Mei L, Gao H, Cai W, Zhu P, Shi K, et al. Synergistic dual-ligand doxorubicin liposomes improve targeting and therapeutic efficacy of brain glioma in animals. Molecular Pharmaceutics. 2014; 11: 2346\u20132357.","DOI":"10.1021\/mp500057n"},{"key":"ref125","doi-asserted-by":"publisher","unstructured":"Kwan BH, Zhu EF, Tzeng A, Sugito HR, Eltahir AA, Ma B, et al. Integrin-targeted cancer immunotherapy elicits protective adaptive immune responses. The Journal of Experimental Medicine. 2017; 214: 1679\u20131690.","DOI":"10.1084\/jem.20160831"}],"container-title":["Frontiers in Bioscience-Landmark"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/31\/7\/10.31083\/FBL47669","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:19:24Z","timestamp":1785413964000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/31\/7\/10.31083\/FBL47669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":125,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"alternative-id":["S2768-6701(26)03261-0"],"URL":"https:\/\/doi.org\/10.31083\/fbl47669","relation":{},"ISSN":["2768-6701","2768-6698"],"issn-type":[{"value":"2768-6701","type":"print"},{"value":"2768-6698","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"article-number":"47669"}}